Poly(DL-lactic acid) scaffolds as a bone targeting platform for the co-delivery of antimicrobial agents against S. aureus-C.albicans mixed biofilms

• Type: Article in International Scientific Journal
• Date: 2022

Authors

Zegre, M (Author) Other; Barros, J (Author) Other; Ribeiro, IAC (Author) Other; Santos, C (Author) Other; Caetano, LA (Author) Other; Goncalves, L (Author) Other; Fernando Mendes Monteiro (Author) FEUP; Ferraz, MP (Author) FEUP; Bettencourt, A (Author) Other

Journal

Title: International Journal of Pharmaceutics

Vol. 622

ISSN: 0378-5173

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 6 Citations

Scopus - 6 Citations

Scientific classification

CORDIS: Health sciences ; Technological sciences

FOS: Engineering and technology ; Medical and Health sciences

Other information

Authenticus ID: P-00W-JSS

DOI: 10.1016/j.ijpharm.2022.121832

Abstract (EN): New strategies for the treatment of polymicrobial bone infections are required. In this study, the co-delivery of two antimicrobials by poly(D,L-lactic acid) (PDLLA) scaffolds was investigated in a polymicrobial biofilm model. PDLLA scaffolds were prepared by solvent casting/particulate leaching methodology, incorporating minocycline and voriconazole as clinically relevant antimicrobial agents. The scaffolds presented a sponge-like appearance, suitable to support cell proliferation and drug release. Single- and dual-species biofilm models of Staphylococcus aureus and Candida albicans were developed and characterized. S. aureus presented a higher ability to form singlespecies biofilms, compared to C. albicans. Minocycline and voriconazole-loaded PDLLA scaffolds showed activity against S. aureus and C. albicans single- and dual-biofilms. Ultimately, the cytocompatibility/functional activity of PDLLA scaffolds observed in human MG-63 osteosarcoma cells unveil their potential as a next-generation codelivery system for antimicrobial therapy in bone infections.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 12